tradingkey.logo
tradingkey.logo
Search

Dermata Therapeutics Inc

DRMA
Add to Watchlist
1.185USD
+0.005+0.42%
Close 07-31 16:00ETQuotes delayed by 15 min
4.77MMarket Cap
LossP/E TTM

DRMA Cash Flow Statement

You can access the annual and quarterly cash flow statements of Dermata Therapeutics Inc to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
-28.21%-2.48M
54.38%-1.33M
47.24%-1.80M
-26.55%-2.69M
28.49%-1.93M
-153.95%-2.91M
-92.98%-3.42M
-15.52%-2.13M
-63.94%-2.70M
37.15%-1.15M
30.83%-1.77M
-0.05%-1.84M
36.74%-1.65M
-1.20%-1.83M
-15.89%-2.56M
-103.66%-1.84M
-235.97%-2.61M
-236.57%-1.80M
-61.36%-2.21M
-21.42%-903.21K
43.71%-776.22K
---535.97K
---1.37M
---743.89K
---1.38M
Net income from continuing operations
19.79%-1.85M
40.91%-1.86M
46.68%-1.69M
39.87%-1.70M
26.50%-2.30M
-47.66%-3.15M
-84.57%-3.17M
-66.28%-2.83M
-39.91%-3.13M
-27.81%-2.13M
29.09%-1.72M
37.69%-1.70M
19.60%-2.24M
34.60%-1.67M
-41.55%-2.42M
-105.03%-2.73M
-20.88%-2.79M
-544.15%-2.55M
-186.73%-1.71M
-62.09%-1.33M
-62.18%-2.30M
---396.31K
---597.39K
---821.65K
---1.42M
Operating gains losses
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
--0.00
--322.00
Other non-cash items
----
----
--731.69K
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-99.03%156.00
-99.49%78.00
-75.62%13.89K
--8.81K
--16.13K
--15.18K
--56.98K
Change in working capital
-303.20%-675.29K
142.51%503.22K
43.90%-149.67K
-250.48%-1.03M
311.10%332.33K
-75.82%207.51K
-45.30%-266.76K
353.00%683.54K
-134.28%-157.43K
327.75%858.20K
50.60%-183.59K
-142.92%-270.18K
1428.23%459.25K
-244.80%-376.82K
41.92%-371.67K
100.15%629.49K
-109.75%-34.58K
1848.86%260.23K
18.83%-639.94K
402.55%314.51K
2434.02%354.75K
---14.88K
---788.35K
--62.58K
---15.20K
-Change in inventory
---93.09K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-Change in prepaid expenses
-198.67%-85.43K
-61.80%65.43K
33.22%-247.70K
-53.85%126.15K
-8.31%86.58K
13.13%171.28K
11.17%-370.90K
7.63%273.38K
-46.00%94.42K
-26.10%151.40K
18.05%-417.55K
-44.12%254.00K
726.18%174.85K
-20.38%204.87K
-36.68%-509.52K
216.87%454.51K
88.64%-27.92K
6454.05%257.31K
-473.80%-372.78K
-1106.16%-388.89K
-1269.13%-245.72K
--3.93K
---64.97K
--38.65K
--21.02K
-Change in other current liabilities
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
---500.00K
----
----
Cash from non-recurring investing activities
Cash from operating activities
-28.21%-2.48M
54.38%-1.33M
47.24%-1.80M
-26.55%-2.69M
28.49%-1.93M
-153.95%-2.91M
-92.98%-3.42M
-15.52%-2.13M
-63.94%-2.70M
37.15%-1.15M
30.83%-1.77M
-0.05%-1.84M
36.74%-1.65M
-1.20%-1.83M
-15.89%-2.56M
-103.66%-1.84M
-235.97%-2.61M
-236.57%-1.80M
-61.36%-2.21M
-21.42%-903.21K
43.71%-776.22K
---535.97K
---1.37M
---743.89K
---1.38M
Investing cash flow
Cash from non-current investing activities
Financing cash flow
Cash flow from continuous financing activities
-77.59%1.90M
6206.42%4.19M
-100.28%-12.99K
-123.42%-547.86K
--8.49M
-103.51%-68.57K
13131.36%4.62M
54.71%2.34M
-100.00%0.00
--1.95M
-17809.50%-35.42K
-64.64%1.51M
--4.18M
100.00%0.00
-100.00%200.00
--4.28M
-100.00%0.00
-100.20%-626.00
937.99%14.39M
-100.00%0.00
--1.58M
--313.33K
--1.39M
--867.85K
--0.00
Net cash flow from debt Issuance/repayment
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--1.01M
--313.33K
--1.37M
--617.85K
--0.00
Net cash flow from common stock issuance/repurchase
-76.65%1.99M
6123.75%4.19M
-100.28%-12.62K
-122.73%-547.86K
--8.54M
-103.56%-69.51K
12933.26%4.55M
59.39%2.41M
-100.00%0.00
--1.95M
---35.42K
-64.64%1.51M
--4.17M
--0.00
-100.00%0.00
--4.28M
----
----
--15.39M
----
----
----
----
----
----
Net cash flow from preferred stock issuance/repurchase
----
----
----
----
----
----
----
----
----
----
----
----
----
----
100.00%0.00
--0.00
-100.00%0.00
--0.00
-5433.33%-1.00M
-100.00%0.00
--570.00K
--0.00
--18.75K
--250.00K
--0.00
Proceeds from issuance of warrants
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
--977.00
--941.00
--168.00
-100.00%0.00
-100.00%0.00
--0.00
-100.00%0.00
-60.92%34.00
--153.00
--0.00
--200.00
--87.00
----
----
----
----
----
----
----
----
----
Net cash flow from other financing activities
-80.91%-91.35K
--0.00
-100.52%-367.00
100.00%0.00
---50.49K
--0.00
--70.00K
---70.83K
100.00%0.00
--0.00
--0.00
--0.00
---40.00
----
----
----
----
---626.00
----
----
----
----
----
----
----
Net cash from non-recurrent financing activities
Net cash from financing activities
-77.59%1.90M
6206.42%4.19M
-100.28%-12.99K
-123.42%-547.86K
--8.49M
-103.51%-68.57K
13131.36%4.62M
54.71%2.34M
-100.00%0.00
--1.95M
-17809.50%-35.42K
-64.64%1.51M
--4.18M
100.00%0.00
-100.00%200.00
--4.28M
-100.00%0.00
-100.20%-626.00
937.99%14.39M
-100.00%0.00
--1.58M
--313.33K
--1.39M
--867.85K
--0.00
Net cash flow
Beginning cash balance
137.92%7.52M
-24.08%4.66M
31.00%6.48M
105.32%9.72M
-57.50%3.16M
-7.35%6.14M
-41.37%4.95M
-46.00%4.73M
19.18%7.44M
-17.79%6.63M
-20.60%8.44M
7.03%8.77M
-42.20%6.24M
-35.99%8.07M
2387.79%10.63M
515.67%8.19M
1935.97%10.80M
1573.65%12.60M
-42.01%427.20K
117.13%1.33M
-73.37%530.40K
--753.05K
--736.70K
--612.74K
--1.99M
Current period cash flow changes
-108.79%-576.70K
195.83%2.86M
-251.82%-1.82M
-1617.36%-3.24M
342.48%6.56M
-469.70%-2.98M
166.22%1.20M
165.02%213.42K
-207.09%-2.70M
144.19%806.65K
29.44%-1.81M
-113.47%-328.23K
196.84%2.53M
-1.16%-1.83M
-121.03%-2.56M
369.81%2.44M
-425.97%-2.61M
-710.50%-1.80M
74376.35%12.18M
-828.62%-903.21K
158.01%800.01K
---222.65K
--16.35K
--123.96K
---1.38M
Ending cash balance
-28.54%6.95M
137.92%7.52M
-24.08%4.66M
31.00%6.48M
105.32%9.72M
-57.50%3.16M
-7.35%6.14M
-41.37%4.95M
-46.00%4.73M
19.18%7.44M
-17.79%6.63M
-20.60%8.44M
7.03%8.77M
-42.20%6.24M
-35.99%8.07M
2387.79%10.63M
515.67%8.19M
1935.97%10.80M
1573.65%12.60M
-42.01%427.20K
117.13%1.33M
--530.40K
--753.05K
--736.70K
--612.74K
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

What is operating cash flow?

Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Dermata Therapeutics Inc Generate?

Dermata Therapeutics Inc generated -7.76M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Dermata Therapeutics Inc's Operating Cash Flow Change Year Over Year?

Dermata Therapeutics Inc's operating cash flow increased by 30.51% year over year.

What is investing cash flow?

Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

What is financing cash flow?

Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Dermata Therapeutics Inc's Financing Cash Flow Changed?

Dermata Therapeutics Inc used 12.12M in financing activities in the latest quarter.

What is free cash flow and why does it matter for DRMA?

Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.